Shattuck Labs provided a corporate update and highlighted upcoming key milestones anticipated in 2023. Clinical Milestones Expected in 2023: ARC Platform – SL-172154: Complete data from Phase 1 dose-escalation clinical trial of SL-172154 as monotherapy in platinum-resistant ovarian cancer expected midyear 2023; Initial data from Phase 1B clinical trial of SL-172154 in combination with liposomal doxorubicin in platinum-resistant ovarian cancer expected midyear 2023; Initial dose-escalation data, as monotherapy and in combination with azacitidine, for Phase 1A/B clinical trial of SL-172154 in AML and HR-MDS expected in 1H’2023 ; Complete dose-escalation data, as monotherapy and in combination with azacitidine, for Phase 1A/B clinical trial of SL-172154 in AML and HR-MDS and initial dose-expansion cohort data expected in 2H’2023; Initial data from Phase 1B clinical trial of SL-172154 in combination with mirvetuximab soravtansine in platinum-resistant ovarian cancer expected 2H’2023. SL-279252: Go/no-go decision from the Phase 1 dose-escalation clinical trial of SL-279252 in advanced solid tumors or lymphoma in 1Q’2023 GADLEN Platform – GADLEN Preclinical Product Candidates: Additional clinical development detail and further program guidance regarding the advancement of potential product candidates from the GADLEN platform in 2023
Published first on TheFly
